Aplagon筹集7M欧元,将其用于血栓炎疾病的APAC药物推广到第2A阶段试验中。 Aplagon raises €7M to advance its APAC drug for thrombo-inflammatory diseases into Phase 2A trials.

赫尔辛基生物技术Aplagon筹集了700万欧元,用于将其APAC药物纳入治疗血栓炎疾病的2A阶段试验。 Helsinki-based biotech Aplagon raised €7 million to advance its APAC drug into Phase 2A trials for treating thrombo-inflammatory diseases. 在Fåhraeus Startup和欧洲创新理事会的领导下,这笔资金将支持外围动脉疾病和慢性危及肢体的缺血症等条件的试验。 Led by Fåhraeus Startup and the European Innovation Council, the funding will support trials for conditions like peripheral arterial disease and chronic limb-threatening ischemia. APAC在40多个病人中表现出毫无安全顾虑的希望,提供了长效抗血清和抗炎行动。 APAC shows promise with no safety concerns in over 40 patients, providing long-lasting antithrombotic and anti-inflammatory action.